GCP
IMCR icon

GSA Capital Partners’s Immunocore IMCR Stock Holding History

GSA Capital Partners’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,039
Closed -$406K – 1793
2024
Q3 		$406K Buy
+13,039
New +$474K 0.03% 1048
2022
Q4 		– Sell
-4,892
Closed -$230K – 1653
2022
Q3 		$230K Buy
+4,892
New +$233K 0.03% 1121

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

GSA Capital Partners's IMCR Position: Q4 2024 in Review

GSA Capital Partners sold out of Immunocore (IMCR) in Q4 2024, closing a stake of 13,039 shares — an estimated $406K sold.

GSA Capital Partners first reported a position in IMCR in Q3 2022 and held it in 2 quarters. The position peaked at $406K in Q3 2024. 115 funds tracked by Wall St. Rank hold IMCR as of Q4 2024.

  • GSA Capital Partners reported no remaining Immunocore position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 13,039 Immunocore shares in Q4 2024, an estimated $406K.
  • GSA Capital Partners first reported a position in Immunocore in Q3 2022 and held it in 2 quarters.
  • GSA Capital Partners's Immunocore position peaked at $406K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Immunocore as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.